Login / Signup

Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study.

Omar Abdel-Rahman
Published in: The clinical respiratory journal (2018)
Number of metastatic sites is the most important predictive factor for overall and PFS among patients with extensive-stage SCLC treated with systemic chemotherapy within a clinical trial.
Keyphrases
  • phase iii
  • clinical trial
  • open label
  • phase ii
  • double blind
  • squamous cell carcinoma
  • small cell lung cancer
  • placebo controlled
  • locally advanced
  • study protocol